Possible contribution of IGF-1 to depressive disorder
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Depression is an illness of unknown origin and involves the dysregulation of many physiological processes disturbed in this disease. It has been postulated that the pathomechanism of depression is complex, and apart from changes in neurotransmitters, a dysregulation of the immune and endocrine systems also plays an important role in the development of this disorder. Recent studies indicate that an impairment of synaptic plasticity in specific areas of the central nervous system (CNS), particularly the hippocampus, may be an important factor in the pathogenesis of depression. The abnormal neural plasticity may be related to alterations in the levels of neurotrophic factors. On this basis, a theory connecting the occurrence of depression with disturbances in neurotrophic factors has gained great attention. This review summarizes data suggesting a role for the neurotrophic factors - especially insulin-like-growth factor-1 (IGF-1) - as possible targets for therapy in depression in the context of depressive behavior modulation, anti-inflammatory action and neuroprotection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IGF-1 has been designated as a potential therapeutic target for neurodegenerative diseases such as MDD (Szczesny et al. 2013).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Szczesny et al. 2013
In the citing paper
“Although clinical studies showed somewhat inconsistent findings, they however mainly revealed higher IGF-1 levels in the serum of depressed patients, which declined during effective antidepressant treatment (Bot et al. 2016; Kopczak et al. 2015; Szczesny et al. 2013).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Szczesny et al. 2013
Citations
Cites
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710 · cited 4×
“In summary, IGFBPs may play a key role in the regulation of brain IGF-1 levels by the following: a) controlling IGF-1 transport in the plasma and its diffusion and efflux from the vascular space; b) increasing the half-life of IGFs and slowing down the loss of their biological activity; c) providing access to specific…”
BackgroundInfluentialInsulin-like growth factors and their binding proteins: biological actions
Jones, J. I. (1995) · Endocrine Reviews · doi:10.1210/er.16.1.3 · Cited by 2,060
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780 · cited 1×
“pression of BDNF [41].”
Peripheral Infusion of IGF-I Selectively Induces Neurogenesis in the Adult Rat Hippocampus
Åberg, M. A. I., Åberg, N. D., Hedbäcker, H., Oscarsson, J., & Eriksson, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02896.2000 · Cited by 852 · cited 1×
“[1] found that in hypophysectomized rats infused with IGF-1, a six-day treatment significantly increased the proliferation of neural progenitors in the hippocampus of adult animals.”
BackgroundRole of Neurotrophic Factors in the Etiology and Treatment of Mood Disorders
Duman, R. S. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:011 · Cited by 537 · cited 1×
“Alterations of the hippocampus, prefrontal cortex or amygdala have been linked to changes in the expression or levels of neurotrophic factors such as brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), nerve growth factor (NGF) and recently insulin-like growth factor (IGF-1) [9].”
BackgroundThe Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain
Russo, V. C., Gluckman, P. D., Feldman, E. L., & Werther, G. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0024 · Cited by 492 · cited 9×
“it controls the efficiency of synapses by influencing processes involved in their formation, the release of neurotransmitters and the excitation of neurons [37].”
BackgroundInfluentialCentral administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects
Hoshaw, B. A., Malberg, J. E., & Lucki, I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.007 · Cited by 348
Aguado, F., Carmona, M. A., Pozas, E., Aguiló, A., Martínez-Guijarro, F. J., Alcantara, S., Borrell, V., Yuste, R., Ibañez, C. F., & Soriano, E. (2003) · Development · doi:10.1242/dev.00351 · Cited by 302 · cited 1×
“In line with this theory, the Aguado group [2] found that IGF-1 receptors were present on serotonergic neuron cell bodies in the raphe and co-localized in the hippocampus with projections from the raphe, thus possibly leading to the direct activation of serotonin release.”
BackgroundMasi, G., & Brovedani, P. (2011) · CNS Drugs · doi:10.2165/11595900-000000000-00000 · Cited by 260
O’Connor, J. C., McCusker, R. H., Strle, K., Johnson, R. W., Dantzer, R., & Kelley, K. W. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.09.010 · Cited by 238
Research works printed but not linked: 2
- Park, 2011, Insulin-like growth factor-I pepides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolisaccharide, J Neuroinflamm, 8, 1
- Wysokiński, 2008, Neurotrophins – actual knowledge (Polish), Post Psychiat Neurol, 17, 385
Cited by
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Numakawa, T., Odaka, H., & Adachi, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113650 · Cited by 353
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
“IGF-1 has been designated as a potential therapeutic target for neurodegenerative diseases such asMDD (Szczesny et al. 2013).”
BackgroundDepression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Metadata
- Authors
- Szczęsny, E., Ślusarczyk, J., Głombik, K., Budziszewska, B., Kubera, M., Lasoń, W., & Basta-Kaim, A.
- Affiliations
- Maj Institute of Pharmacology (PL)
- Venue
- Pharmacological Reports
- Published
- 2013-11
- Volume
- 65
- Issue
- 6
- Pages
- 1622-1631
- ISSN
- 1734-1140 (ISSN-L)
- OpenAlex
- W1968946286
- Cited by
- 68
- References
- 42
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 7 · 2023: 4 · 2022: 2 · 2021: 10 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 5 · 2016: 6 · 2015: 7 · 2014: 1 · 2013: 1
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- green
- ruj.uj.edu.pl
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Pharmacological Reports (publishedVersion)
- PubMed (publishedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- Depression-Mechanisms-Therapy (POIG. 01.01.02-12-004/09-00)
- European Regional Development Fund
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- insulin-like growth factor I, depression, neurotrophic factors, synaptic plasticity, hippocampus, neuroprotection, anti-inflammatory activity, immune dysregulation, endocrine dysfunction, antidepressant targets, depression-like behavior
- MeSH terms
- Animals, Antidepressive Agents, Central Nervous System, Depressive Disorder, Humans, Insulin-Like Growth Factor I, Nerve Growth Factors, Neuronal Plasticity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Possible contribution of IGF-1 to depressive disorder. https://app.cochat.ai/papers/10.1016/s1734-1140(13)71523-8
- The paper
- Szczęsny, E., Ślusarczyk, J., Głombik, K., Budziszewska, B., Kubera, M., Lasoń, W., & Basta-Kaim, A. (2013). Possible contribution of IGF-1 to depressive disorder. Pharmacological Reports. https://doi.org/10.1016/s1734-1140(13)71523-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.